| |
|
 |
Accumetrics, Inc.
Accumetrics, Inc. is an innovative developer and manufacturer of diagnostic instrumentation and test kits located in Sorrento Valley. The company is committed to advancing medical understanding of platelets and enhancing quality of care for patients at a risk of cardiovascular disease by providing industry-leading diagnostic tests for platelet function assessment. The company developed the VerifyNow™ System, the first, simple and accurate system for measuring the individual response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix ®, ReoPro ®, and Integrilin ® the VerifyNow™ System provides a valuable tool to help guide treatment decisions.
back to top
|
 |
Alereon,
Inc.
Alereon, Inc. is a fabless semiconductor company using revolutionary
ultrawideband (UWB) radio technology to develop high-bandwidth, low-power,
low-cost Wireless USB and WiMedia UWB chipsets that are ideal for today’s
personal computer and portable products, including digital cameras, Mp3
players, and cell phones. Alereon’s mission is to replace the complex tangle
of wires that interconnect today’s electronic devices with wireless links.
back to top
|
 |
Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is an interventional medical device company focusing on "natural orifice" procedures. Also known as transgastric endoscopy (TGE), the field promises to revolutionize minimally invasive surgery, allowing for the first time scarless surgical procedures conducted by entering the peritoneal cavity through a hole in the stomach. With this new portal, a new class of procedures can be developed for the treatment of obesity, reflux, and general surgical procedures in the peritoneal cavity. The company is based on the intellectual energy of the Apollo Group -- widely known as the world's most respected thought leaders in therapeutic endoscopy and in minimally invasive surgery.
back to top
|
 |
Asuragen, Inc.
Asuragen, Inc. is a fully integrated diagnostics company focused on
molecular oncology and early detection of cancer, with emphasis on microRNA.
Asuragen’s current diagnostic product portfolio consists of Signature ®
Genetic Testing and Oncology Testing products, as well as industry leading
controls and standards engineered using its patented Armored RNA ®
technology. Asuragen is dedicated to developing new technologies that will
become cutting edge clinical products. In addition to being empowered with high level scientific
expertise, Asuragen has a strong business infrastructure, GLP testing
services and an established cGMP manufacturing facility that allows it to
span the spectrum of discovery, testing, production, and commercialization.
back to top
|
 |
BioForm
Medical, Inc. (NASDAQ: BFRM)
BioForm Medical, Inc. (NASDAQ: BFRM) is a medical aesthetics company
dedicated to bringing doctors and their patients safe and effective products
for use in the dermatology, plastic surgery, and ear, nose and throat (ENT)
markets. BioForm’s products include Radiesse ®, a long-lasting filler for use
in facial aesthetics and vocal fold insufficiency, and Coaptite ® for
treating female stress urinary incontinence. Additionally, BioForm has
licensed U.S. marketing rights to Aethoxysklerol ®, the worldwide leading
sclerotherapy agent, which is currently being evaluated in a Phase III
clinical trial. BioForm has also licensed BioGlue, a new surgical adhesive
product for plastic surgery applications, which is being developed in a
partnership with CryoLife, Inc.
back to top
|
 |
BioMimetic Therapeutics,
Inc. (NASDAQ: BMTI)
BioMimetic
Therapeutics, Inc. (NASDAQ: BMTI) is developing and commercializing
bio-active recombinant protein-device combination products for the
healing of musculoskeletal injuries and disease, including orthopedic,
spine and sports injury applications. BioMimetic received marketing
approval from the FDA for its first product, GEM 21S ®. The company's
product and lead product candidates all combine recombinant protein
therapeutics with tissue specific scaffolds to actively stimulate
tissue healing and regeneration.
back to top
|
 |
BioSurface
Engineering Technologies,
Inc.
BioSurface Engineering Technologies, Inc. (“BioSET”) is developing
proprietary therapeutic peptides for incorporation into medical devices to
improve bone and soft tissue repair. BioSET's synthetic peptides are
bioactive mimetics of growth factors that continue to show promising results
in studies for the treatment of musculoskeletal, vascular, and chronic wound
diseases. The company intends to capitalize on the growing interest in
drug/device combination products and seeks to initiate studies of these
combination products in human clinical trials.
back to top
|
 |
Cameron Health, Inc.
Cameron Health, Inc., a development stage medical device
company, is creating the next generation of implantable electronic
device utilizing state-of-the-art technologies. The company is comprised
of a team of specialized, high technology, creative individuals with
decades of experience in solving difficult medical problems. The current
target is the development of a family of devices that will afford
patient treatment that has been, until now, unattainable with the
current therapeutic modalities and technologies.
back to top
|
 |
Cardiva Medical, Inc.
Cardiva
Medical, Inc. is a privately held medical device company focused on
developing and commercializing devices which close the vascular access
site. Cardiva’s first product, the Boomerang™ Wire System, was approved
in EU countries and in the U.S. in 2004. Cardiva’s second-generation
product, the Boomerang Catalyst™ System launched in July 2007. This
product uniquely provides the control to achieve rapid hemostasis with
early patient ambulation, eliminate implant-related complications and
allow immediate re-access. The enhanced Boomerang Catalyst™, trade
named as “Boomerang Catalyst™ II System” received 510(K) clearance in
September 2007 and launched in January 2008.
back to top
|
 |
GlycoMimetics,
Inc.
GlycoMimetics, Inc. ("GMI") capitalizes and builds on advances in the
field of glycobiology by developing small molecule drugs that mimic the
action of carbohydrates. The initial focus is on therapeutics to treat
inflammatory diseases and cancer. GMI acquired the assets of GlycoTech and
builds upon a platform technology for designing and screening carbohydrate
mimics. The technology was developed through collaboration between GlyoTech
and Ciba-Geigy (later Novartis). GMI owns or has exclusive licenses to
fifteen issued U.S. patents. The company’s two lead drug candidates are in
pre-clinical development.
back to top
|
 |
IDEV
Technologies, Inc.
IDEV Technologies, Inc. (“IDEV”) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery, and cardiology device marketplace. IDEV is based in Houston, Texas and its current portfolio contains over thirty technologies exclusively licensed from the M.D. Anderson Cancer Center, representing over a $5 billion market opportunity worldwide. The current focus is on the successful commercialization of a novel interwoven nitinol design of the SUPERA™ stent for use in hepatic biliary disease.
back to top
|
 |
InSite Vision, Inc.
(INSV.OB)
InSite Vision, Inc. (“ISV”) (INSV.OB) develops novel topical
anti-infective products for eyes and ears, including AzaSite®
(azithromycin
ophthalmic solution) 1% which was launched in the U.S. by Inspire
Pharmaceuticals, Inc. for the topical treatment of bacterial conjunctivitis
(pink eye). ISV is pursuing the expansion of its portfolio of anti-infective
ophthalmic products to include ISV-502 (AzaSite Plus™) in Phase III pivotal
trials as a product candidate directed at treating eye and eyelid infections
and inflammation, currently an unmet need. In addition, ISV is evaluating
the use of its product platform for ear infections with the product
candidate, AzaSite Otic™ in preclinical development. The company is also
developing AzaSite Xtra, a product designed to assist in penetrating
international markets.
back to top
|
 |
Intersect ENT, Inc.
Intersect ENT, Inc. is a medical device company that is pioneering novel
therapies for Ear, Nose & Throat (ENT) physicians to utilize in
providing improved treatment for their patients. Their initial product
is a therapeutic device for patients with Chronic Sinusitis, one of the
most common chronic conditions affecting one out of seven adults in the
United States. Chronic Sinusitis causes debilitating symptoms and has a
greater impact on quality of life than congestive heart failure or
chronic back pain. Through a combination of internal talent, plus input
from leading physicians, Intersect ENT plans to continue developing novel new
products for the ENT community from the application of its proprietary
platform technology.
back to top
|
 |
LDR
Spine USA, Inc.
LDR Spine USA, Inc. (“LDR”) is a privately held
orthopedic spine company with a full line of spinal
implant devices. Managed by an executive team that
spun-out of Centerpulse Orthopedics, the company is a
joint venture with LDR Medical, a French venture backed
company with strong spinal product design expertise. The
core group of LDR Medical has been together for fifteen
years and previously designed the ProDisc™ (a first
generation lumbar disc implant). To build upon the
success of the ProDisc™, LDR developed a second
generation artificial disc technology resulting in
creation of the Mobidisc ® and Mobi-C ®.
back to top
|
 |
Mirna
Therapeutics, Inc.
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage
biotechnology research and development company focused
on miRNA-directed oncology therapies. Featuring
world-class research capabilities, a strong
understanding of miRNA and cancer biology, and a broad
IP portfolio, Mirna Therapeutics is well-positioned to
capitalize on the emerging field of miRNA-based
therapeutics.
back to top
|
 |
On-X Life Technologies, Inc.
On-X Life Technologies, Inc. ("On-X LTI") is the world leader in pyrolytic carbon technology, with emphasis on prosthetic devices. In addition to their own product lines, On-X LTI helps other medical device companies develop and manufacture products that incorporate On-X® carbon, their proprietary pure pyrolytic carbon. On-X® carbon is the first major advance in pyrolytic carbons in over 30 years. On-X LTI designed and manufactures the On-X® Prosthetic Heart Valve, the most advanced prosthetic heart valve available. With its innovative features, the On-X® valve provides maximum patient benefits
back to top
|
|
 |
Ortho Kinematics, Inc.
Ortho Kinematics, Inc. is a functional diagnostics company
created to capitalize on the shortage of diagnostic
information surrounding spine procedures. Furthermore, Ortho
Kinematics will be well positioned in the new healthcare
environment of cost reduction by payers who desire more
information surrounding medical device efficacy and matching
the most appropriate procedure for the right patient to
ensure the best outcome. The company was a recipient of a
$1.5 million State of Texas Emerging Technology Fund Award,
which will further help the company commercialize its
products.
back to top |
 |
OsteoBiologics, Inc.
OsteoBiologics, Inc. ("OBI"), acquired by Smith & Nephew,
develops and manufactures bioabsorbable polymeric scaffolds, films, and
related instrumentation for the repair and replacement of bone, soft tissue
and articular cartilage. OBI's primary product marketed, TruFit™ CB, is a
one-step arthroscopic procedure for repairing bone and articular cartilage
defects.
back to top
|
|
 |
Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
back to top
|
|
 |
ZIOPHARM
Oncology, Inc. (NASDAQ: ZIOP)
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) is a biopharmaceutical company engaged in the
development and commercialization of a diverse, risk-sensitive portfolio of
in-licensed cancer drugs to address unmet medical needs. The company applies
new insights from molecular and cancer biology to understand the efficacy
and safety limitations of approved and developmental cancer therapies and
identifies proprietary and related molecules for better patient treatment.
back to top |
| |
|
